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P1 - Acquired rhinophyma as a paraneoplastic manifestation of non-small cell 
lung cancer
 Denis Baricevic,  Marko Jakopovic,  Marinka Baricevic
Department of Respiratory Diseases ‘Jordanovac’, University Hospital Center Zagreb, Croatia
We report a case of a 58-year-old man who developed rhinophyma caused by non-small cell lung 
cancer.
This paraneoplastic manifestation was set because of chronological coincidence between the disap-
pearance of the rhynophyma and chemoradiotherapy and the appearances of rhinophyma and the pro-
gression of the disease.
The patient is a 58-year-old male who was treated for diabetes, when he developed rosacea for which 
he was unsuccessfully treated with antibiotic therapy. He was admitt ed to our hospital, due to chest pain 
persisting for 55 days, fever up to 37.4 C, fatigue and 7 kg weight loss. On chest radiography was found 
irregular infi ltrate with central collapse on right upper lobus and thickening of apical pleura. Follow-up 
computed tomography imaging confi rmed the presence of a consolidation infi ltration while follow-up 
cytological analysis of material gained by catheter aspiration revealed carcinoma (poorly preserved squa-
mous cells). Due to the advanced stage of the disease (stage IIIA), patient was treated both with chemo-
therapy (4 cycles of neoadjuvant therapy (gemcitabine and cisplatin)) and radiotherapy. During chemora-
diotherapy the withdrawal of rhinophyma has occurred and computed tomography imaging showed 
regression of the disease from stage IIIA to stage IIB, for which patient soon underwent right thoracotomy 
with upper lobectomy and radical lymph node dissection. Two months after surgery, patient experienced 
re-emergence of rhinophyma followed by increased tumor markers (CYFRA 21-1 was 4.5) for which he 
received second-line chemotherapy (4 cycles of paclitaxel and carboplatin). After 2nd cycle of chemother-
apy rhinophyma has again withdrawn and the patient experienced remission of the disease. Two month 
after chemotherapy subsequent whole body F18- FDG positron emission tomography (PET) was per-
formed and documented metastasis on right lung, second and third rib and suprarenal gland. The patient 
received erlotinib therapy after which once again experienced remission of rhinophyma for a brief time 
(one month), since he due to progression of carcinoma passed away shortly thereafter.
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P2 - UGT1A1*28 polymorphism and toxicity of FOLFIRI protocol 
– a single-institution cohort
 Ivan Bilić1,  Nada Božina2,  Lana Ganoci2,  Marko Kralik3,  Stjepko Pleština1,  Damir Vrbanec1
1Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia 
2Clinical Unit for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, 
University Hospital Center Zagreb, Croatia 
3Department of Diagnostic and Interventional Radiology, University Hospital Center Zagreb, Croatia
Treatment with irinotecan in combination with infusional 5-FU, is still one of the pillars of oncologic 
approach to patients with metastatic colorectal cancer. Unfortunately, toxic collateral damage to normal 
tissues produces many side-eﬀ ects of the drugs. UDP-glucuronyl transferase (UGT1A1) is the rate-limit-
ing enzyme of the irinotecan metabolism, responsible for bulk degradation of injected compound (up to 
80%). Fluoropyrimidines are to similar extent inactivated by dihydropyrimidine- dehydrogenase (DPD). 
Genes for these two metabolic enzymes can harbor pathogenic polymorphisms resulting in partial or com-
plete enzyme-defi ciency leading to disturbed pharmacokinetics as well as increased risk for toxicity. Phar-
macogenetic testing may give valuable information for individualization of therapy as defi ciency can be 
detected by UGT1A1 and DPYD genotyping. Most common UGT1A1 variant among Caucasians is 
UGT1A1*28, resulting in Gilbert’s syndrome among homozygotes, with signifi cantly increased risk for 
irinotecan-induced side eﬀ ects. Whether heterozygotes for UGT1A1*28 also have diminished tolerability 
of irinotecan requiring dose-reduction is still a matt er of debate. We have found scarce published data on 
prevalence of UGT1A1*28 polymorphisms among oncologic patients of Croatian descent. DPYD-locus 
may be aﬀ ected by few dozens of variants with uncertain functional relevance. No signifi cant data was 
published on genetic background considering DPYD among patients of this geographic region. Here we 
present the preliminary results of a single-institution patient cohort genotyped for UGT1A1*28 and some 
major DPYD variants and followed-up for toxicity during irinotecan/5-FU therapy (FOLFIRI-protocol).
FOLFIRI-treated patients (N=114) were genotyped for UGT1A1*28 as well as for fi ve major DPYD-
polymorphisms (*2A, *13, c.2846A>T, c.1236G>A and c.496A>G). Adverse events were monitored for three 
months from the beginning of treatment. Observed group included grade III and IV toxicity (N=52), 
whereas control group comprised grade I and II (N=62). DNA was isolated from whole blood (3ml) and 
genotyped according to manufacturer’s propositions using real-time PCR (LightCycler® for UGT1A1, Taq-
Man® for DPYD). Frequencies of the polymorphisms were tested by non-parametric statistical tests and 
binary logistic regression.
A total of 206 adverse events were recorded during observation period (75 of high and 131 of low 
grade). Subjects in observed group (toxicity grade III and IV) developed adverse eﬀ ects more rapidly and 
accumulated greater total number of events per capita. UGT1A1*28 polymorphism was detected in 58% of 
tested subjects. Both homozygotes and heterozygotes were at signifi cantly increased risk for toxicity 
(OR=20.58 and 5.47 respectively). Aggregated DPYD polymorphisms (N=33; 28.9%) distributed unevenly 
with higher frequency of carriers in observed group (38.46% vs. 20.97%), thus creating a statistically sig-
nifi cant increase of risk for severe toxicity among carriers of mutated DPYD variant (OR=2.36). UGT1A1*28 
variant had stronger infl uence on toxicity-risk than DPYD polymorphisms considering patients given iri-
notecan in combination with 5-FU, as expected form literature.
Signifi cant association and predictive value of UGT1A1*28 polymorphism among patient given FOL-
FIRI-protocol is shown, while mutation status of DPYD has shown weaker but still signifi cant infl uence. 
Frequencies of detected polymorphisms were in slight discordance considering data from literature, thus 
emphasizing importance of genetic background among diﬀ erent genotyped ethnic groups.
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P3 - Preclinical evidence on the anticancer properties of phytocannabinoids
 Biljana Blažeković,  Marija Kindl,  Maja Bival Štefan,  Mateja Mervić,  Sanda Vladimir-Knežević
Department of Pharmacognosy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia
Phytocannabinoids are unique terpenophenolic compounds predominantly produced in the glandu-
lar trichomes of the cannabis plant (Cannabis sativa L.). The delta-9 tetrahydrocannabinol (THC) is the main 
active constituent responsible for the plant’s psychoactive eﬀ ect and, together with the non-psychoactive 
cannabidiol (CBD), the most investigated naturally occurring cannabinoid. The fi rst report on the antitu-
mor properties of cannabis compounds appeared more than forty years ago, but the potential of targeting 
the endocannabinoid system in cancer has recently att racted increasing interest.
Our study aimed to review the last decade’s fi ndings on the anticancer potential of plant-derived can-
nabinoids and the possible mechanisms of their activity.
A large body of in vitro data has been accumulated demonstrating that phytocannabinoids aﬀ ect a 
wide spectrum of tumor cells, including gliomas, neuroblastomas, hepatocarcinoma as well as skin, pros-
tate, breast, cervical, colon, pancreatic, lung and hematological cancer. It has been found that they can stop 
the uncontrolled growth of cancer cells through the cell-cycle arrest, inhibition of cell proliferation and 
induction of autophagy and apoptosis. They can also block all the steps of tumor progression, including 
tumor cell migration, adhesion and invasion as well as angiogenesis. The observed eﬀ ects are mainly 
mediated by the cannabinoid CB1 and/or CB2 receptors, although some other receptors and mechanisms 
unrelated to receptor stimulation may also be involved. The majority of available animal studies con-
fi rmed that phytocannabinoids are capable of eﬀ ectively decreasing cancer growth and metastasis in vivo. 
THC was found to be eﬀ ective against experimental glioma, liver, pancreatic, breast and lung cancer while 
CBD showed activity against glioma and neuroblastoma, melanoma, colon, breast, prostate and lung can-
cer. Further in vitro and in vivo studies also greatly support their use in combination with traditional che-
motherapy or radiotherapy, which results in improved eﬃ  ciency, att enuated toxicity or reduced drug 
resistance. Taken together most of available preclinical results emphasize the extensive therapeutic poten-
tial of THC and CBD in various types of cancers. The potential clinical interest of cannabinoids is addition-
ally suggested by their selectivity for tumor cells as well as their good tolerance and the absence of normal 
tissue toxicity, which are still the major limitations of most conventional drugs. The accumulated preclini-
cal evidence strongly suggests the need for clinical testing of cannabinoids in cancer patients.
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P4 - Colon carcinoma with a metastasis into breast, a case study
 Mislav Čonkaš1,  Sara Šošić1,  Luka Kužat1,  Zvonimir Magaš1,  Marijan Žvorc1,  Slavko Gašparov2
1County Hospital Čakovec, Croatia 
2Clinical Hospital Merkur, Zagreb, Croatia
In August, 2009, a 55-year-old female patient visited her doctor because of abdominal pain. Endos-
copy verifi ed a malignant process of the ascendental colon whose PHD corresponded to adenocarcinoma. 
Right-side hemicollectomy with ileotransversal anastomosis was done; regarding the third stage of the 
illness, in further treatment adjuvant chemotherapy was carried out in 6 cycles – 5FU/LV.
After 2 years a control evaluation showed a relapse on the anastomosis and multiple metastases on 
the lungs. A resection of the local relapse was done after which the patient was treated with chemotherapy 
through combined protocol based on irinotecan with a good response and regression of the number and 
size of the pulmonal metastases. Then a thoracotomy with radical metastasectomy of the two remaining 
metastases of the right lower lobe. In June 2013, a control PET-CT test again shoved a suspected local 
relapse of the illness so that a repeated surgery was indicated. Intraoperative fi ndings confi rmed a relapse 
on the anastomosis, so a resection of the transversal colon and terminal ileum was done. In the postopera-
tive period the patient underwent 3 chemotherapy cycles according to CapeOx protocol after which the 
control evaluation did not show any clear signs of the illness activity.
In March 2015, owing to severe abdominal pain and a suspected illness relapse there was a repeated 
surgery. Intraoperatively a tumor size 18 cm was verifi ed having originated in the left ovary which had 
spontaneously ruptured with metastases in the small intestines and sigmoid colon. A surgery of sigmoid 
colon resection according to Hartmann was done, also a resection of the metastases on the small intestines, 
hysterectomy with adnexectomy on both sides and extirpation of the tumor on the left ovary. PHD fi nding 
confi rmed metastatic adenocarcinoma, so the patient was consequently treated with chemotherapy accord-
ing to FOLFOX IV protocol. After 5 cycles a control PET-CT was done which showed a metabolically active 
node in the right breast, without any signs of active illness in other parts of the body. A carcinoma was 
cytologically confi rmed so in November 2015 a tumor extirpation was done.
Immunohistochemical analysis proved a secondary process, ER neg, PR neg, HER-2 neg, Ki67 70% 
with present expression CEA, CK20, CDX2 neg. 2 months later the patient was hospitalized with a clinical 
picture of obstructive ileus. Intraoperatively an inoperable solid malignant block with inset bowel folds – 
from the surgical point of view an incurable condition. Regarding the surgical fi ndings and a deterioration 
of the general condition a confi rmed active oncological treatment was given up and palliative care was 
indicated.
Metastases into a breast of other primary tumors are rare consuming only about 2% of all breast 
metastases. Lymphomas, metastatic melanoma and bronchi carcinoma are those that account for the 
majority of breast metastases.
Breast metastases of the colorectal carcinoma have been described in literature in very few cases and 
point to an expansive and agressive illness where surgical treatment and a systemic oncological treatment 
have a very limited role.
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P5 - The use of Edmonton Symptom Assessment System (ESAS) in patients 
with metastatic melanoma at the time of admission to Medical Oncology 
Clinic (MOC), Institute for Oncology and Radiology of Serbia (IORS)
 Jelena Dimitrijevic,  Snezana Bosnjak,  Fedja Djordjevic,  Natasa Bakic,  Natasa Lazin,  Iva Kezic
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
ESAS has been proposed as a symptom screening tool in cancer patients. It consists of numerical rat-
ing scales (0-10) for self-assessment of eight most common cancer-related symptoms as well as patient’s 
well-being, with a 10th scale for a patient-specifi c symptoms. The goal of this study was to examine the use 
od ESAS as an inital symptom screening tool in patients with metastatic melanoma at the time of admis-
sion to MOC, IORS.
During a four week study period, patients with metastatic melanoma assessed disease-related symp-
toms using an ESAS at the time of admission. Descriptive statistics methods were used to analyze collected 
data.
Symptoms were assessed in 12 patients (7 male and 5 female). Median age was 63 years (range 35-80) 
with median performance status (PS) of 1 (range 0-3). All nine ESAS symptoms were reported as less than 
4 by majority of patients with mean scores of 1.73, 0.70, 1.61, 0.57, 2.03, 1.53, 1.03, 1.18 and 2.06 for pain, 
nausea, loss of appetite, shortness of breath, fatigue, depression, drowsiness, anxiety and well-being, 
respectively.
This study has shown that the ESAS is practical and not time-consuming tool for initial assessment of 
cancer-related symptoms in patients with metastatic melanoma at the time of admission at the MOC, 
IORS. Further research will be conducted in order to examine the role of ESAS in assessment of symptom 
burden in these patients and its impact on treatment decision-making process.
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P6 - Infl uence of molecular subtypes of metastatic breast cancer 
on clinical manifestations and disease outcome
 Ivana Durutović,  Vladimir Todorović
Clinic for Oncology and Radiotherapy, Podgorica, Medical faculty, University of Montenegro
The breast cancer is the third cause of cancer-related mortality in Europe, after lung and colorectal 
cancers. According to Ferlay et al. breast cancer incidence in Montenegro is 75.9/100.000, while mortality 
rate is 27.6/100.000. In Montenegro, breast cancer is not just the most frequent cancer in women, but also 
the fi rst cause of cancer related death.
Aims of this study were establishing metastatic breast cancer molecular subtypes distribution, cor-
relation between metastasis patern and molecular subtype, as well as correlation between molecular sub-
type and clinical parameters.
The research was conducted on a sample of 214 women, who were diagnosed with breast cancer 
relapse in form of distant metastasis in time 6 years long time period (2006 till end of 2012). Minimal follow 
up period was 24 months, till the end of year 2014.
Every patient was classifi ed into one of four groups, with usage of available immunohistochemical 
approximation: 1. Luminal A like ( Er+, Pr+, HER 2 0); 2. Luminal B like (Er+, Pr+/-, HER 2 +); 3.HER 2 (Er-, 
Pr-, HER 2 +); 4.Triple negative (Er-, Pr-, HER 2 0).
Median age at metastatic disease diagnosis was 58.2 years. Out of total number of patients, 56% had 
the luminal A molecular subtype, 18% had the HER2 subtype, 16% had the triple negative subtype, while 
the least frequent, at only 10%, was the luminal B molecular subtype. The patients with HER2 subtype 
developed brain metastasis more frequently than those with the other subtypes (p=0.023). The patients 
with luminal subtypes A and B more frequently developed bone metastasis, as the fi rst and the second site 
of relapse (p<0.001). Patients with HER2 and triple negative subtype had more frequently paliative radio-
therapy as treatment (p<0,001).
The patients with the HER2 and triple negative subtypes had shorter cumulative survival comparing 
to those with luminal subtypes (p=0.011). Median time to progression was 15 months. According to our 
results, time to progression in patients with the HER2 and triple negative subtypes was shorter than aver-
age (p=0.027), respectively 11.6 and 12.4 months. At point of two years follow up, only 35% of HER2 sub-
type patients and 40% of patients with the triple negative subtype were alive, in contrast with the signifi -
cantly larger proportion of patients with the luminal subtypes. Metastatic sites, time to progression and 
survival varied by subtype as approximated by ER, PR and HER2. The HER2 subtype was a predictor of 
worse outcomes and poor survival.
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P7 - The eﬃ  cacy and tolerability of slow-release (SR) hydromorphone 
in the treatment of cancer dyspnea in lung cancer patients: experience 
from the Institute for oncology and radiology of Serbia (IORS)
 Feđa Đorđević,  Nemanja Stanić,  Jelena Dimitrijević,  Jelena Spasić,  Ana Žilić,  Snežana Bošnjak, 
 Davorin Radosavljević,  Snežana Šušnjar
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Cancer related dyspnea and pain are common in patients with lung cancer. Morphine is an eﬀ ective 
medication for both symptoms. Oral SR morphine is not available in Serbia. Oral SR hydromorphone is 
used instead. The eﬃ  cacy and tolerability of immediate-release (IR) hydromorphone in the treatment of 
cancer dyspnea was documented in the literature.
Objective of our study was to assess the eﬃ  cacy and tolerability of oral SR hydromorphone (24h 
release) for the treatment of cancer pain and dyspnea in lung cancer patients.
Twenty fi ve patients with lung cancer with severe dyspnea and pain (both assessed on 0-10 numeric 
rating scale) were included. On day 1 (D1) patients were treated with oral IR morphine 5 mg Q4h with the 
same dose  for the breakthrough pain and dyspnea. In all patients who required at least 30 mg of oral IR 
morphine for 24 hours period, SR hydromorphone 8 mg were included in the treatment on day 2 (D2) with 
IR morphine 5 mg forforthe breakthrough pain and dyspnea. On D2-D5 the eﬃ  cacy and tolerability of SR 
hydromorphone as well as adverse eﬀ ects were monitored.
On D1, the mean intensity of dyspnea was 7.48(SD=0.510). On D5 all patients were still on 8 mg of SR 
hydromorphone without the need of morphine for the breaktrough pain or dyspnea. On D5 the mean 
intensity of dyspnea was 2.48(SD=0.770), with signifi cantly less intensity compared to D1 (p<0.001). There 
were no registered side eﬀ ects of SRhydromorphone.
Use of convenient SR hydromorphone resulted in sustained relief of dyspnea as well as pain with 
acceptable tolerability.
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P8 - Metastatic renal cell carcinoma: First-line treatment choice 
in everyday practice – personal experience
 Milena Gnjidić1,  Dino Dujmović2
1Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia 
2Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Croatia
Over the past decade marked advances in treatment of metastatic renal cell carcinoma (mRCC) have 
been made, with targeted agents that inhibit vascular endothelial growth factor and its receptor ( VEGF, 
VEGFR) or mammalian target of rapamycin complex ( mTOR). Standard therapies for fi rst-line treatment 
of metastatic good and intermediate risk clear-cell renal cell carcinoma are sunitinib and pazopanib also 
approved by Croatian Institute for Health Insurance. COMPARZ study has demonstrated that both drugs 
have similar eﬃ  cacy but diﬀ erent side-eﬀ ect profi les. There are no recommendations or predictive bio-
markers to help in choosing between them and the choice is mainly based on clinical parameters. Besides, 
patients in routine clinical practice are not similar to those enrolled into clinical trials. When high-level 
evidence is not available for treatment decisions, personal experience or medical community might pro-
vide guidance.
We performed this retrospective comparative analysis of mRCC patients treated between 2014 to 2016 
at our insitution in order to try to identify parameters infl uencing the choice between the two drugs. Four-
teen patients recieved sunitinib and 19 pazopanib. We analysed following parameters: sex, age, place of 
residence, MSKCC risk group, number of metastatic sites, prior nephrectomy, tumor grading, number of 
comorbidities. We also analysed progression-free survival (PFS) and overal survival (OS).
The two groups did not diﬀ er signifi cantly according to sex, age, place of residence, number od 
metastatic sites and prior nephrectomy. There was a trend towards prescribing sunitinib more frequently 
to patients with more aggressive disease (higher MSKCC risk group and tumor grade) but the diﬀ erence 
was not statistically signifi cant. Patients with two and more comorbidities more frequently received pazo-
panib (p=0.036). No diﬀ erences in PFS and OS between the groups were noted.
We prescribed pazopanib more frequently to patients with comorbidities and had a slight tendency 
to prefer sunitinib in patients with high-risk tumors. There were no diﬀ erences in survival outcomes 
between the two groups. These results are consistent with known large real-life studies.
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P9 - When to stop the treatment of venous thromboembolism in cancer patients
 Robert Grubišić-Čabo,  Ivan Krečak,  Matilda Kinkela,  Filip Grubišić-Čabo
Department of Internal medicine - General Hospital Šibenik, Croatia
Despite adequate anticoagulation treatment cancer patients who gets venous thromboembolic ( VTE) 
complication have, comparing to general population, higher incidence of rethrombosis, but also of bleed-
ing. It is generally accepted that these patients should be treated with anticoagulations for 3-6 months. 
Such an att itude is a consequence of 3 randomised trials, in this fi eld, in which the patients have been 
treated for 3 months, as well as the fact that in the largest study they have been treated for 6 months. As a 
consequence of absence of trials, which would resolve the problem of continuation or withdrawl of the 
therapy after 3-6 months of treatment, we make our decisons based on estimation of the value/risk of con-
tinuation anticoagulation treatment, regarding the risk of rethrombosis, risk of bleeding; tolarebility of the 
treatment; patients choice as well as the acitivity of malignant tumor.
Lib Oncol. 2017;45(Suppl. 1), 45–81
54
P10 - Malignancy-related ascites; clinical signifi cance and impact on prognosis
 Petra Jurčić1,  Ivan Budimir2,  Marko Nikolić2,  Dominik Kralj2
1Department of Medical Oncology and Radiotherapy, University Hospital for Tumours, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia 
2Department of Gastroenterology and Hepatology, Division of Internal Medicine, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
The appearance of malignancy-related ascites usually heralds the onset of advanced disease and por-
tends a poor prognosis. We conducted a retrospective study of 43 patients who underwent therapeutic 
abdominal paracentesis for malignancy-related ascites between October 1st, 2015 and March 31st, 2016 at 
our institution. The population included 23 males and 20 females with a mean age of 64 years (range, 22-81 
years) diagnosed with metastatic disease, the most common of which included gastrointestinal cancer (28 
patients) and ovarian cancer (7 patients). The sites of metastases at diagnosis of the ascites as demon-
strated by diagnostic imaging techniques included liver (19 patients), lymph nodes (18 patients), perito-
neum (13 patients), lung and pleura (5 patients), bones (3 patients), and rare metastatic sites (3 patients). 
The most frequent symptoms of the malignancy-related ascites were abdominal distension (90.7%), short-
ness of breath (34.9%), abdominal discomfort or pain (16.3%), leg swelling (16.3%), vomiting (11.6%), nau-
sea (9.3%), constipation (4.7%) and general weakness (4.7%). The mean volume drained by paracentesis 
was 4000 milliliters per procedure (range, 1200 milliliters to 6000 milliliters). Diuretics were used in 30 
patients with furosemide used in 29 (67.4%), spironolactone in 18 (41.9%) and combination of both in 17 
(39.5%). None of the patients in this series had either continuous peritoneal ports or catheters drainage. 
The patients with gastrointestinal cancer had higher values of serum urea (13.6 mmol/L) than other (7.4 
mmol/L) (p=0.0323). The values of serum urea in the patients with gastrointestinal cancer were also greater 
than in the patients with ovarian cancer (6.9 mmol/L) (p=0.0392). The patients with liver metastases on 
average were older (72 years) than the other patients (63 years) (p=0.0169), and had higher values of serum 
bilirubin (36.4 μmol/L) than other (10.6 μmol/L) (p=0.0292) as well. The patients with nausea had higher 
values of serum urea (20.15 mmol/L) than the other (7.8 mmol/L) (p=0.0384). The patients presented with 
swollen legs had signifi cantly lower INR than the other (p=0.0365). The survival period after the patients 
were diagnosed with ascites was between 2 and 339 days (the median value was 24 days). The patients 
with ovarian cancer had the average survival period of 93 days (between 5 and 339 days). The patients 
with gastrointestinal cancer had an average survival period of 35 days (between 2 and 201 days). Regard-
ing the primary cancer diagnosis, the survival analysis showed a statistically signifi cant diﬀ erence in the 
dynamics of mortality (p=0.0352). Three patients with ovarian cancer died within 20 days, and the other 
four lived for about a year. Nearly all patients with gastrointestinal cancer died within three months. After 
abdominal paracentesis, the patients with liver metastases lived for 19 days on average (3 to 149 days), 
while the patients without liver metastases lived for 86 days on average (2 to 339 days) (p=0.0120).
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P11 - Eﬃ  cacy and safety of antivascular drug after anti-EGFR; afl ibercept 
after panitumumab, a clinical case
 Petra Jurčić
Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
A 40-year-old male with a negative family history of cancer and longstanding extensive ulcerative 
colitis, who was treated with mesalazine, was referred in July 2016 for a regular follow-up colonoscopy. A 
stenotic cancer in the hepatic fl exure was detected with the histological fi nding of poorly diﬀ erentiated 
adenocarcinoma. Comprehensive whole-body imaging revealed the multiple bilobar liver metastases and 
the absence of pulmonary and bone metastases. The patient underwent right hemicolectomy. The defi ni-
tive pathological investigation confi rmed the previous histological fi ndings, pT4a (focal perforation of 
serosa) R0 pN2 [4/56] pM1[hep] pL1, pV1, pPn0, G3, wild-type RAS. The perioperative upper-extremity 
deep venous thrombosis was treated as a paraneoplastic feature. The patient was assigned to mFOLFOX6 
and panitumumab as the fi rst-line treatment protocol. During this treatment, the patient developed papu-
lopustular rash of the face and the trunk grade 2 NCI-CTCAE v.4.0. Additional mutation screening revealed 
the presence of PIK3CA mutation in exon 9 (E542K) and the absence of BRAF mutations in primary cancer 
and lymph node metastases. A daily 100 mg dose of acetylsalicylic acid was added to standard therapy. 
After four cycles, the increment of serum markers (CEA, CA19-9) was noticed. Computed tomography 
scan of the abdomen revealed progression in size of liver metastases. Due to liver-limited disease, the mul-
tidisciplinary tumor board did not exclude the possibility of resection. Consequently, FOLFIRI and afl iber-
cept were introduced in January 2017. After two cycles, the serum markers were in signifi cant decrease. 
After four cycles, the values of serum markers were halved. The abdominal computed tomography scan 
fi ndings suggested a constant size of liver metastases but with central necrosis. Due to the omitt ed unac-
ceptable gastrointestinal toxicity, it was decided to continue with the same line for the next four cycles. 
After the fi fth cycle, the asymptomatic arterial hypertension second-degree NCI-CTCAE v.4.0 occurred. 
Nevertheless, it was kept under control with antihypertensive. The next appointment for diagnostic imag-
ing and laboratory test is scheduled for May 2017.
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P12 - Long–term chemiosensitivity of epithelial ovarian cancer: case report
 Kristina Juskic,  Ljiljana Stamatovic,  Marijana Milovic-Kovacevic
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
The signifi cance of ovarian cancer is disproportionaly larger than its frequency, because, although it 
counts less than a quarter of gynecological malignancies, it is a cause of mortality of half of the women 
with gynecological cancer. Epithelial ovarian cancer is the most common type of cancer and most of EOC 
are diagnosed in advanced stage.
Although it is a highly sensitive tumour, with accomplishment of signifi cant percentage of remission 
on fi rst chemoherapy , about 75% of women relapse in the fi rst three years. The standard treatment of rec-
curent EOC is successive apply of several therapy lines, and secondary citoreduction is indicated in 
selected cases.
Specifi c treatment of epithelial ovarian cancer of initial stage IIIA, at our patient, started in 2007, with 
total hysterectomy with billateral adnexectomy and omentectomy. In NED stage of the disease, postop-
erative therapy with paclitaxel - carbopatine was conducted.
Two years after, in the fi rst relapse, patient received four cycles of ChT Taxol-CBDCA. Further use of 
this protocol was stopped because of allergic reaction to carboplatine.
Treatment was continued with weekly paclitaxel, and after the second cycle, disease progression was 
registered, and the secondary ChT regimen PAC was introduced. Five cycles of secondary ChT were 
administered, with the eﬀ ect of CR.
In July 2012, PD was verifi ed, and nine cycles of gemcitabine with bevacizumab were administered 
with the eﬀ ect of PR. Considering eﬀ ect and hematological toxicity, maintenance therapy with bevaci-
zumab was continued. Thirteen cycles were applied, with the eﬀ ect PD, so salvage chemotherapy weekly 
paclitaxel – cisplatine started.
After the fourth cycle, PR was declared ,but, due to peripheral sensory neuropathy grade 3, chemo-
therapy was suspended. Pregabaline was induced as neurological toxicity therapy, which led to recovery 
to the grade which made possible repeated use of cisplatine.
Six months after, disease progressed, when Taxol-CDDP was rechallanged. After the fourth cycle 
evaluation showed PR, but due to deterioration of peripheral neuropathy to grade 3, citostatic therapy was 
withdrawn.
In August 2015, PD was verifi ed, so, with recovery of peripheral sensory neuropathy to grade 2, sen-
sitivity to cisplatine, cummulative dosage of doxorubicine, fi ve cycles of doxorubicine – cisplatine were 
administered.
Fifth cycle was administered on November 2015, with the eﬀ ect PR, with prolonged hematological 
and moderate non hematological toxicity. Repeated progression was manifested in six months , and cis-
platine – cyclophosphamide was conducted next 5 months with the eﬀ ect of PR.
This case report presents a nine years long course of disease of the patient with advanced EOC. 
Patient had a clinically signifi cant partial response to each platinum regimen, which is why this case is an 
example of a very chemiosensitive cancer. Unfortunately, through the course of time, duration of good 
response was reduced from initial 24 months to 6 months in the last approach.
Our patient`s case represents a rare example of chemiosensitive disease which has signifi cantly 
exceeded overall average survival, characteristic to epithelial ovarian cancer, and, at the same time, the 
course of treatment illustrates the importance of individually tailored therapy.
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P13 - Response to treatment with topotecan in patient with recurrent ovarian 
cancer considering sensitivity to the platinum
 Kristina Katić,  Višnja Matković,  Ante Ćorušić
Department of Gynecologic Oncology, Clinical Department of Gynecology and Obstetrics, University Hospital 
Centre Zagreb, Croatia
Ovarian cancer is a chemosensitive disease and most of the patients with ovarian cancer have a good 
response to the fi rst line therapy. Despite of this, 80% of patients will develop recurrence of the disease, 
most often within the fi rst two years. Topotecan is one of the options of treatment in relapse. In Croatia, 
topotecan is available in the second and third line therapy of patient with ovarian cancer.
In retrospective study we included 80 patients with ovarian cancer treated with topotecan in our 
institution in the period from 01.05.2011. to 31.12.2014. The response to treatment with topotecan we ana-
lyzed according to RECIST criteria. The patients were divided in 2 groups: 1. who received topotecan as a 
second line (39 patients) 2. who recieved topotecan as a third line (41 patients). The each group was divided 
considering to the platinum sensitivity to: 1. refractory 2. resistant 3. sensitive disease.
In the fi rst group responded 5 of 7 patients (71%) with platinum refractory disease, 7 of 24 patients 
(29%) with platinum-resistant disease, and 4 of 8 patients (50%) with platinum sensitive disease. In the 
second group responded 6 of 15 patients (40%) with platinum refractory disease, 2 of 15 patients (13%) 
with platinum-resistant disease and 9 of 11 patients (82%) with platinum sensitive disease.
Topotecan had similar eﬃ  cacy in the second and in the third line therapy of recurrent ovarian cancer, 
but more complete responses and a longer time to progression has been observed in patients who received 
topotecan as the third line. The best response to treatment has been observed in patients with platinum 
sensitive disease.
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P14 - Epidemiologic analysis of patients with testicular cancer during a 5-year 
period in the Referral center for treatment of germ cell tumors and extragonadal 
germ cell tumors in Republic of Croatia
 Ana Koši Kunac1,  Zrna Antunac Golubić1,  Milena Gnjidić1,  Iva Zubatović Đunđenac1, 
 Željko Kaštelan2,  Marija Gamulin1
1Department of Oncology, Division of Medical Oncology, Unit of uro-oncology, Referral center for treatment 
of germ cell tumors and extragonadal germ cell tumors in Republic of Croatia, University Hospital Center Zagreb, 
Croatia 
2Department of Urology, University Hospital Center Zagreb, Croatia
Testicular cancer accounts for approximately 1% of all malignancies in men, but is the most common 
cancer of younger male population, with the highest incidence between ages 15 and 35. Given that testicu-
lar cancer cannot be prevented, it is necessary to diagnose the disease in early stages, because of higher 
cure rates. If the disease is found early, curability is about 95%, and in advanced stages of the disease cur-
ability falls to 60%. Given the published data on the above average increase in the incidence of testicular 
cancer in Croatia for 7% from the year 1983 to 2007, and projected increase in the incidence of testicular 
cancer by 72% by the year 2025, we analyzed data of testicular cancer patients in the Department of Oncol-
ogy, University Hospital Center Zagreb. The aim of the research was to obtain a clear picture of the inci-
dence of advanced stage of testicular cancer patients over fi ve years categorized by Croatian counties, so 
we could redirect educational programs aimed at raising awareness of the testicular cancer in the most 
vulnerable areas. In a retrospective study conducted at the Department of Oncology, we analyzed data on 
patients treated from January 2012 to December 2016. Data were collected using hospital system BIS, and 
were analyzed by patient age, stage of disease and the county of origin. During the fi ve-year period, the 
total number of newly diagnosed patients with testicular cancer was 461, mostly between the ages of 30-35 
years. The largest number of patients were from Zagreb, including Zagreb County, followed by Brod-
Posavina and Koprivnica-Križevci County. Considering the data from Croatian National Institute of Pub-
lic Health incidence of testicular cancer, about 50% of all newly diagnosed patients with testicular cancer 
in Republic of Croatia were examined and treated in the Department of Oncology, University Hospital 
Center Zagreb. During the fi ve-year period, we identifi ed a trend of reduction in newly diagnosed patients 
with advanced-stage testicular cancer by 20% to 8%. The majority of patients with advanced stage at diag-
nosis originated from Zagreb and Zagreb County, followed by Međimurje and Karlovac County. Given 
the impossibility of preventing testicular cancer, substantially higher cure rates can be achieved by early 
detection. This is further enhanced by public relation media for the purpose of informing and educating 
targeted male population. Such propaganda was conducted with a campaign for early detection of testicu-
lar cancer, Počeši s razlogom, which began in March 2016 and won this year’s Grand Prix and a gold award 
Croatia Eﬃ  e.
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P15 - Lung cancer – experience of a small center
 Anamarija Kovač Peić,  Matea Kršan,  Zvjezdana Borić Mikez,  Ivana Vučinić Ljubičić, 
 Hrvoje Holik,  Božena Coha
General Hospital ‘Dr. Josip Benčević’ Slavonski Brod, Croatia
Objective of this study was to determine median overall survival of the patients treated of lung cancer 
at the Department of hematology and oncology General hospital Dr. Josip Benčević in Slavonski Brod, also 
we analized characteristics of patients and treatment based on medical records. Retrospectively we anal-
ized data of 195 patients treated in period of 40 months from 09/2013 to 12/2016. It was 151 men (77.4%) 
and 44 women (22.6%), median age at the time of diagnosis was 65 years range form 43 to 81 years. There 
were 84% patients with non small lung cancer (NSCLC), 42% had squamous lung cancer, 31% adenocarci-
noma, 9% adenosquamous or large cell carcinoma, 2% large cell neuroendocrine carcinoma, 16% patient 
had smal cell lung cancer. Of all NSCLC 5% had EGFR mutation, and only 4% of patient had ALK deter-
mined. Concerning staging 1.2% classifi ed as stage I, 3.5% as stage II, 22.5% as stage III and unfortunately 
majority of them 72.8% patients as stage IV. Most of them were smokers (74%) and routinely drinking 
alcohol (27%). At the time of dijagnosis 60% of patients met criteria for cahexia diagnosis. After the fi rst 
examination of medical oncologist 15 patients (7.7%) were send to thoracic surgery, and 7 patients (3.5%) 
were operated after neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy. Chemotherapy was 
administered primarily in outpatients environments. We analized numbers od chemotherapy lines during 
treatment of each patient: 46% of patients received only one line of treatment, 27% received two lines, 18% 
three lines, four and more lines of chemotherapy was given to 9% of patients. Time to progression in fi rst 
line of treatment was 6.6 months. With concomitant chemoradiotherapy we treated 10% of patients, pal-
liative radiation 18% of patients and intrapericardial chemotherapy for pericardial tamponade in 4 patients 
(2%). Neutropenia durig fi rst line of treatment was identifi ed in 10% of patients, due to complications of 
treatment 50% of patients was admitt ed to our hospital department one or two times, but 22.% patients 
were never hospitalized. One year survival was 38.6%. Median overal survival was 11.79 months. Due to 
new studies in lung cancer that are chaging perspectives for some patients recently treated with chemo-
therapy and prolong survival we hope that for our patients molecular diagnostic methods will be more 
available in order to select potential candidates for already approved but also for novel treatments in era 
of individualized oncology treatment.
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P16 - What is the future of hormone receptor positive HER2 negative metastatic 
breast cancer treatment?
 Lucija Kovačević,1  Natalija Dedić Plavetić,2  Damir Vrbanec2
1University Hospital Center Zagreb, Croatia 
2Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, School of Medicine, 
University of Zagreb, Croatia
It is estimated that approximately one out of every eight Croatian women will develop invasive breast 
cancer over the course of their lifetime. Breast cancer is a heterogeneous disease comprising diﬀ erent 
clinical, histopathological, and molecular subtypes. Estrogen receptor (ER) is expressed in approximately 
70% of newly diagnosed breast cancers and has an important role in tumor growth and progression. Endo-
crine therapy forms the backbone of treatment for hormone-dependent breast cancer. Despite the benefi ts 
of endocrine therapy, resistance occurs in a large number of patients and represents an important clinical 
challenge in the management of breast cancer.
Mechanisms of endocrine resistance and future therapeutical strategies:
Endocrine resistance occurs as intrinsic (de novo) or acquired, depending on duration of initial 
response to endocrine therapies. The most important future approach for treating HR+ breast cancer is one 
that involves overcoming endocrine resistance. Understanding already identifi ed mechanisms of resis-
tance to endocrine therapies helps us in development of novel potential drugs to overcome resistance. The 
most important mechanisms of endocrine resistance are: 1. changes in the ER signalling pathway and its 
coregulators 2. Increased activity or overexpression of tyrosine kinase receptors (RTKs) 3. Increased activ-
ity of proteins regulating cell defense mechanisms (Akt, PI3K, mTOR) 4. Changes of cell cycle regulatory 
proteins (Myc, Cyclin D1). Most of them are results of genomic and epigenomic changes in tumor cells, 
rarely are refl ections of tumor microenvironment and host infl uences.
The combination of mTOR inhibitors with endocrine agents has been incorporated into clinical prac-
tice after the publication of the BOLERO 2 trial, a randomized phase III study which demonstrated sig-
nifi cant improvement in PFS with the addition of the mTOR inhibitor everolimus to the steroidal AI 
exemestane.
A new strategy in treating patients with ER-positive breast cancer is to target cyclin-dependent 
kinases 4 and 6 (CDK4/6), a key pathway involved in regulation of the G1/S transition of the cell cycle. At 
the present time, there is no evidence demonstrating a role of specifi c biomarkers other than ER, PR, and 
HER2 in the clinical management of HR+ advanced breast cancer. Use of other biomarkers is considered 
experimental and currently should be limited to clinical trials only.
Metastatic breast cancer still remains an incurable disease for most patients. Advances in understand-
ing tumor biology, particularly signaling pathways, have led to the development and approval of many 
novel agents. Here we present the well-known mechanisms that lead to the development of resistance to 
the endocrine treatment as well as the current and future treatment options based on the mechanisms 
involved.
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P17 - Imatinib as second-line treatment for inoperable progressive mesenterial 
desmoid tumor and familial adenomatous polyposis – a case report
 Tatjana Ladenhauser
Oncology Department, University Hospital Center Osijek, Croatia
42-years old female patient was hospitalised at the abdominal surgery clinic, where a progressive 
abdominal tumour was under work-up and found to be inoperable. A total colectomy for familial adeno-
matous polyposis (FAP) was performed in the year 2008. The diagnosis of inoperable desmoid mesenterial 
tumour/aggressive fi bormatosis was established 7 years after via laparoscopic biopsy. Patient was then 
treated with tamoxifen 10mg bid during 1 year and with discontinuation, and control CT of the abdomen 
showed progressive disease. Patient suﬀ ered from diarrhea, abdominal tenderness, cystostomy macera-
tion, frequent urinary infections, weight loss and anemia.
Tamoxifen in dose of 40mg bid together with celecoxib 200mg daily was reinduced in treatment as 
escalation in dose of the fi rst-line treatment. After 4 months the tumor progressed in size and symptoms 
with newly spontaneous formation of ileo-tumor-cutaneous fi stula. Second line treatment with imatinib 
mesylate was oﬀ ered in a dose of 400mg daily. After 6 months of imatinib, control CT scan of the abdomen 
showed no progression and stable disease. Patient still had similary symptoms but reduced in frequency 
and intensity. Side-eﬀ ects of imatinib included grade 1 ones: sporadic abdominal pain, fatigue and perior-
bital swelling. Strategy for further treatment is continuation of imatinib in the same dose until the disease 
progression.
Imatinib in daily dose of 400mg as a second-line treatment for an inoperable progressive abdominal 
desmoid tumor was well tolerated and eﬀ ective in this patient. No progression after 6 months and no 
grade 2 or higher side eﬀ ects were observed.
For patients with FAP, total colectomy and subsequent inoperable desmoid tumors, there is a great 
need for eﬀ ective novel therapies and their availability, as well as for possibility for recruitment in clinical 
trials, since this rare disease lacks the standard therapeutical procedures.
Lib Oncol. 2017;45(Suppl. 1), 45–81
62
P18 - Single institution experience in fertility preservaion in female patients 
diagnosed with early stage cancer
 Iva Marinčić,  Petra Vuković,  Jelena Raguž,  Nikolina Vincelj,  Robert Šeparović
Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
This is the review of our experience in fertility preservation in female patients diagnosed with early 
stage cancer. The aim of the review was to show, whether cryopreservation prolonges time until chemo-
therapy.
A retrospecitve study was conducted from March 2015 to March 2017 at the Department of Medical 
Oncology University Hospital for Tumors, Sestre milosrdnice University Hospital Center. Data were col-
lected from medical history.
Out of all female patients which were diagnosed with early stage cancer 40 of them wanted to pre-
serve their fertility. Out of total number 38 patents were diagnosed with early stage breast cancer, and two 
patients were diagosed with colorectal cancer.
Patients were between 25 and 43 (median 34) years of age, and they were treated in adjuvant or neo-
adjuvant sett ing.
All patients were oﬀ ered with cryopreservation of oocytes or embryos with subcutaneous application 
of LHRH agonist, or just LHRH agonist application before the start of chemotherapy application or endo-
crine therapy.
Out of 40 patients nine underwent cryopreservation process. Others opted for monthly subcutaneous 
LHRH agonist application which was conducted during the whole time of chemotherapy application/
endocrine therapy and continued up to three month after last chemotherapy application.
Medical record analysis showed that average time from patients presentation at Multdisciplinary 
team to the fi rst application of chemotherapy was 40.2 days in group that underwent oocyte/embryo cryo-
preservation, and average time for LHRH group was 21.6 days.
Final data of this review is consistent with data available in current literature.
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P19 - Our experience with palbociclib
 Marija Miletić1,  Mirjana Pavlović2,  Ana Tečić Vuger2,  Nikolina Vincelj2,  Iva Marinčić2,  Petra Vuković2, 
 Jelena Raguž2,  Robert Šeparović2
1Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia 
2Department of Medical Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice 
University Hospital Center, Zagreb, Croatia
Clinical eﬃ  cacy of endocrine therapy (ET) is limited with the development of primary (de novo) and 
secondary resistence to ET. Cyclins and cyclin-dependent kinases (CDK) play a key role in cell signaling 
and their dysregulation is one of the mechanisms responsible for the development of endocrine resistance. 
Several clinical studies phase II and III (PALOMA1/TRIO18, PALOMA2 and 3) showed a signifi cant ben-
efi t of the combination of CDK inhibitors (palbocicib, ribociklib, abemaciklib) plus ET.
Thanks to Compassionate Use Program, in our institution treatment with palbociclib began on March 
3, 2016. Since then, the program included 13 patients, seven have been so far treated (three patients in the 
course of active treatment) and fi ve patients had not yet begun treatment. The inclusion criteria are: hor-
mone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic 
breast cancer previously treated with a minimum of four therapy lines for metastatic disease. Before being 
included in the program our patients have previously received an average of fi ve lines of treatment for 
metastatic disease (4-6). Palbociclib is taken orally once daily on a 28-day cycle consisting of 21 days on the 
drug and seven days oﬀ ; letrozole is taken orally once daily. Median age (range) is 61 years (49-72). Neutro-
penia is the most common adverse event.
Dose interruption, dose reduction or delay in starting treatment cycles is not recommended for 
patients who develop grade I or II neutropenia. Three patients had neutropenia grade III, one febrile neu-
tropenia and they were required to temporary discontinue treatment (3-23 days). The most common non-
hematologic adverse events were grade I or II: fatigue (4), nausea (3) and diarrhea (2). The median duration 
of treatment is 15.35 weeks (3-43.5).
Based on our experience we can conclude that palbociclib, in combination with ET, is potentially an 
eﬀ ective therapeutic option, with a consistent safety profi le, in the later lines of treatment luminal, HER2-
negative breast cancer.
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P20 - Unusual pathohistological fi nding in patient with prostate cancer
 Marija Milosavljevic,  Nada Babovic
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Our patinet, was a 74- years- old male with no comorbidities or concomitant medications and no fam-
ily history of malignancy. In january 2008 due to PSA elevation, TURP (transurethral ressection of pros-
tate) was performed and pathohistology report has shown: Adenocarcinoma, G2, Gleason scor 7 (3+4).
Initial PSA was 26.54 ng/ml (point) and bone scan has shown osteoblastic-ostelytic solitary metastasis 
in thoracic vertebre. After 12 cycles with LHRH agonist, we have registered biochemical response with 
decreased PSA level of 0.79 ng/ml. In august 2009 when PSA elevation was detected, retreatment with 8 
cycles of LHRH agonists was performed. In april 2010 we detected a left pleural eﬀ usion /X ray/, general-
ized lymphadenopathy with hydronephrosis grade 2 and urinaryretention / CT scan/, and biochemistry 
report has shown azotemia with abnormal liver function test. PSA was 3ng/ml.
Because of this unusual presentation, progression of disease with low PSA, lymph node biopsy was 
done. Pathohistology and imunohistochemistry report has shown: metastasis of carcinosarcoma wich was 
negative for PSA and PSAP and CD8 and CD20 positive.
In summary, we conclude that metastatic, carcinosarcoma prostate, and PSA -, and PSAP-negative 
prostate carcinoma, is a rare and highly aggressive neoplasm with an associates poor outcome.
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P21 - Clinical outcome in patients with primary advanced or metastatic 
endometrial carcinoma treated with standard chemotherapy regimen according 
diﬀ erent histopathologic characteristics
 Lidija Pavlović,  Marijana Milović–Kovačević,  Anđela Karaferić,  Suzana Vasović,  Ljiljana Stamatović
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Most cancers of the endometrium are of endometrioid histology (type 1 EC). A smaller subset is asso-
ciated with aging and unique genetic/molecular changes, producing a more aggressive variant, serous/
clear cell type/ undiﬀ erentiated (Type 2 cancers). The aim of this study was to investigate diﬀ erence in 
clinical outcome in patients with primary advanced or metastatic endometrial cancer treated with stan-
dard chemotherapy combination consisting of doxorubicin-cisplatin (DOX-CDDP) with regard to histo-
logical subtype.
Eligible patients had histologically-proven advanced and/or metastatic endometrial adenocarcinoma 
and were chemotherapy-naive. Treatment consisted of CDDP 50 mg/m2 combined with DOX 60 mg/m2, 
every 3 weeks. Response rates were evaluated according to RECIST 1.1 criteria. Kaplan Maier method and 
Log rank test were used to assess survival prognostic factors. Median age was 64 years (range 34-77). 
Patients were divided into 2 groups according to histopathology type: Type 1 EC- endometrioid and Type 
2 EC- serous/clear cell/ undiﬀ erentiated type. Between 2007 and 2012., we analysed 18 patients (60%) with 
Type 2 EC (6 papillary serous, 11 clear cell, 1 undiﬀ erentiated) and 12 patients (40%) with Type 1 EC.
Thirty patients underwent hysterectomy and BSO, with or without lymphadenectomy. FIGO stages 
were as follows: FIGO III=18 (60%), FIGO IV=12 (40%). Twelve patients (100%) with Type 1 EC had partial 
and complete remission (responders). Response for Type 2 was as follows: 7 patients (39%) had stable 
disease (SD) and 11 patients (61%) had partial and complete remission (responders). The combination 
DOX–CDDP provided a signifi cantly greater therapy response in Type 1 EC compared to Type 2 EC ( 
Fischer Exact test; p =0.024). At the time of analysis, 76% of patients were still alive after median follow up 
of 21 months (9-58). Median progression free survival (PFS) for Type 1 EC was 18 months (range 8-56), and 
median PFS for Type 2 EC was 11 months (5-26), demonstrating signifi cant TTP diﬀ erence between Type 
1 and Type 2 EC (Log-Rank test; p=0.0014). There was no need for treatment adjustment due to toxicity. 
Neutropenic fever occurred in 1 patient (3%). The most common nonhematological toxicities were fatigue 
grade 1-2 (70%) and nausea grade 2 (42%) while 4% of patients suﬀ ered from peripheral sensory neuropa-
thy grade 1.
Type 2 endometrial cancer is rare and diﬀ ers from Type 1, especially with respect to high frequency 
of distant metastaes. Our results indicate worse outcomes to standard chemotherapy in Type 2 EC com-
pared to Type 1 EC, suggesting multicentric studies are needed to bett er defi ne appropriate management 
of those malignancies.
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P22 - Tolerability of bevacizumab in triple-negative (TNBC) metastatic breast 
cancer patients: a single institution experience
 Marijana Milovic-Kovacevic,  Lidija Pavlovic,  Andjela Karaferic,  Suzana Vasovic,  Ljiljana Stamatovic
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Subset analyses suggest TNBC benefi ts from angiogenic therapy. Bevacizumab signifi cantly improves 
progression-free survival and response rate in fi rst-line metastatic breast cancer when combined with 
paclitaxel. The purpose of this study was to evaluate the safety profi le of bevacizumab in combination 
with paclitaxel in mTNBC patients.
Patients with mTNBC not previously treated with chemotherapy received paclitaxel 80mg/m2/weekly 
on days 1, 8 and 15 every 4 weeks with bevacizumab (compassionate use) 10mg/kg every 2 weeks. Patients 
fullfi lled major baseline requirements: no uncontrolled hypertension, no signifi cant proteinuria and ECOG 
0 or 1. After achieving maximal therapy response to paclitaxel-bevacizumab combination, bevacizumab 
monotherapy was administered until disease progression or unexpected toxicity. Patients were prospec-
tively monitored for overall toxicity and for bevacizumab-related adverse events.
Twenty patients were enrolled to treatment between December 2010 and October 2011. The patient 
population had a rather great metastatic burden: 2 patients had four metastatic sites, 4 had three, 9 had 
two (2 pts with CNS and liver metastases) and 5 patients had one metastatic site. Signifi cantly more 
patients had visceral involvement (liver predominantely) than metastatic disease presented with bone and 
soft tissue metastases. Registered toxicity was as follows: leucopenia grade 3/4 was observed in 3 pts and 
neutropenia gr 3 in 2 patients; hemorrhage/bleeding gr 1 (epistaxis and rectal bleeding) occured in 9 pts; 
proteinuria gr 1 was detected in 4 pts, sensory neuropathy gr 1 in 5 pts and myalgia/arthralgia gr 1 in 5 pts. 
Hypertension gr 1/2 was verifi ed in 4 patients and only one patient had hypertension gr 3 that was also 
satisfactory controlled with antihypertensive therapy. After two cycles one patient experienced wound-
healing complications in breast region which caused an immediate cessation of bevacizumab therapy. 
Potentially life-threatening events such as arterial and venous thromboembolism, gastrointestinal perfora-
tion, bleeding including pulmonary events or left ventricular dysfunction were not registered.
Our results show that the addition of bevacizumab to paclitaxel chemotherapy is relatively safe and 
well-tolerated therapy in routine clinical practice, confi rming predictable adverse events associated with 
bevacizumab therapy. Paclitaxel-bevacizumab combination may be considered as an option for the fi rst-
line treatment of patients with TNBC metastatic breast cancer.
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P23 - Nivolumab induced synchronous occurrence of polymyositis 
and hypothyroidism in a patient with squamous cell lung cancer
 Sonja Badovinac1,  Davorka Muršić1,  Marta Koršić1,  Kamelija Žarković2,  Marko Jakopović1, 
 Branka Čučević1,  Mihovil Roglić1,  Filip Popović1,  Miroslav Samaržija1
1Department of Respiratory Diseases ‘Jordanovac’, University Hospital Center Zagreb, Croatia 
2Department for Pathology and Cytology, University Hospital Center Zagreb, Croatia
Immunotherapy in the treatment of malignant diseases is based on stimulating the patient’s strength 
of immune response against tumor and presents great potential in improving the eﬀ ectiveness of the treat-
ment. Alongside the proven eﬃ  cacy, immunotherapy in treatment of malignant diseases can cause 
immune-related adverse events diﬀ erent from commonly known chemotherapy-related toxicities.
A 63 years old female patient was diagnosed with stage IV squamous cell lung cancer in February 
2015. The fi rst-line treatment was gemcitabine and cisplatin chemotherapy (4 cycles), and soon after disease 
progression second-line treatment, docetaxel, was applied (4 cycles). In March 2016, after disease progres-
sion, patient had started with nivolumab immunotherapy. In the 7th month of nivolumab treatment, the 
patient complained of a symmetric weakness and a pain in proximal muscles of the lower extremities and 
in the shoulder girdle musculature. Creatine kinase (CK) and myoglobin levels were signifi cantly elevated: 
CK level was 2657 U/L while myoglobin level was 226 μg/L. The analysis of thyroid hormones revealed a 
signifi cant hypothyroidism (TSH > 100 000 mIJ/I). Muscle biopsy revealed a damage of muscle fi bers with 
an infl ammatory infi ltration with lymphocytes. Myophagocytosis was present. It was a synchronous occur-
rence of immune-related side-eﬀ ects - polymyositis and hypothyroidism. Immunotherapy was stopped 
and the treatment with systemic corticosteroid and thyroid hormone substitution was introduced. The 
patient reported an improvement in the strength of the aﬀ ected musculature regions with the disappear-
ance of muscle pain. In follow-up laboratory tests CK level started to decrease. Up to this date, one year 
after nivolumab treatment started, the patient is without disease progression, PS ECOG 0.
Immunotherapy can result in synchronous occurrence of immune-related series of side eﬀ ects. These 
side eﬀ ects are signifi cantly diﬀ erent from the side eﬀ ects associated with standard chemotherapy, and if 
they are not recognized and treated in time, they can lead to signifi cant worsening of the patient’s condi-
tion as well as fatal consequences.
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P24 - Survival data on early, invasive breast cancer patients treated with adjuvant 
chemotherapy: ten years follow-up in University Hospital Center Zagreb
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According to the Croatian National Cancer Registry, the incidence rate of breast cancer in 2014was 
119.2/100 000 population while the mortality rate was 44.8/100 000 population, with a total of 2668 new 
diagnosed cases and1071deaths caused by breast cancer during 2014. Breast cancer is the most common 
type of cancer among females in Croatia (26%).
This study was conducted to analyze clinicopathological characteristics and treatment results of early 
breast cancer in subgroup of women with more aggressive subtypes of breast cancers in which systemic 
adjuvant chemotherapy was indicated. We analyzed and compared 5 and 10 year survival data of this 
subcohort of patients with results of the whole cohort diagnosed with early breast cancer in the same 
period.
153 patients were selected from the study cohort of 215 consecutive patients diagnosed with early 
invasive breast cancer in University Hospital Center Zagreb, in a period between September 2002 and 
September 2003. All lymph node positive patients received adjuvant chemotherapy and lymph node neg-
ative patients received adjuvant chemotherapy only if adverse prognostic factors were present (adverse 
tumor grade and size, positive lymphovascular invasion, negative hormone receptor status), together with 
other modalities of adjuvant treatments.
In our study, the group median tumor size was 2.2 cm, dominant tumor grades were 2 and 3, and 40% 
of patients had positive axillary lymph nodes. Lymphovascular invasion was present in 7.2% of all tumors. 
Molecular surrogate subtypes of breast cancer were as follow: luminal A 47.5%, luminal B1 10.4%, luminal 
B2 8.5%, HER2 overexpressed 9.1% and triple negative 24.8%. All our patients have received adjuvant 
chemotherapy without adjuvant trastuzumab for HER-2 subtype: anthracyclines 60.7%, CMF 19.6%, tax-
anes 9.8% and FAC/CMF 9.8%.
During the ten-year follow-up 58 of 153 patients (37.91%) relapsed, and 47 of them (81.03%) relapsed 
in the fi rst fi ve years. The disease free survival (DFS) in fi ve and ten years follow-ups in our subgroup were 
69.28% and 62.09%,whilethe whole group had DFS of 73.97% and 69.90%. The overall survival (OS) in fi ve 
and ten years follow-ups in our group of 153 patients was 83.66% and 71.89%,and in the whole group of 
215 patients was 88.50% and 73.30%, respectively. Out of 215 patients with breast cancer, during the ten-
year follow-up, 62 of them (28.83%) relapsed and 55 of them had died (25.58%).
We can conclude that our subgroup has had worse results of DFS and OS during the fi ve and ten 
years follow-ups in comparison to the group of all 215 breast cancer patients.
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Breast cancer patients who received adjuvant chemotherapy have had a more aggressive disease and 
after adjuvant chemotherapy treatment the most relapses and deaths happened in the fi rst fi ve years of the 
follow-up. In addition, despite adjuvant chemotherapy and other adjuvant treatment modalities, our 
group of breast cancer patients had worse results of DFS and OS during the fi ve and ten years follow-ups 
compared with the group of all 215 patients with early invasive breast cancer.
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Docetaxel is a chemotherapeutic agent from tihe class of taxanes which works by disrupting microtu-
bule function to inhibit cell division. Docetaxel has been proven as a potent agent in treatment of various 
solid malignancies, including metastatic prostate cancer. Most adverse events associated with the use of 
docetaxel have been well documented and are expected, alopecia beeing at the top of the list. Patients are 
informed to expect not only hair loss, but also loss of ovearll body hair, including eyebrows and eyelashes.
Trichiasis is an eyelid abnormality in which the eyelashes are misdirected and grow inwards toward 
the eye. Those inward-turning lashes rub against the cornea the inner surface of the eyelids which leads to 
eye irritation, swelling and redness and in severe cases to scarring of the cornea and vision impairment.
A 62-year old male with no previous comorbidities was diagnosed with prostate cancer after a rou-
tine screeing discovered elevated PSA 14,6. After biopsy and imaging the patient was classifi ed as interme-
diate risk based upon his Gleason score 7 (4+3), and PSA level and underwent radical prostatectomy. PHD 
was adenocarcinoma, GS7, meta lymphonodi, pT3bpN1M0. After surgery the patient received adjuvant 
radiotherapy in combination with ADT that lasted for 3 years. In 4/2011 the patient underwent orchidec-
tomy on the count of biochemical relaps of the disease. He continued with ADT, Kalufar 5 mg. The patient 
was stabile untill 7/2014 when the PSA levels begin to rise, although he had no symptoms and was in 
overall good health. In 10/2014 PSA was 32,6 and imaging methods (CT and PET scan) showed multiple 
metatstic lymph nodes and multidisciplinary team suggested chomotherapy with docetaxel which he 
started in11/2014 and completed in 7/2015. After 2 cycles of chemotherapy the patient lost most of his hair, 
including eyelashes wich didn’t grow back during the 10 cycles of docetaxel he received. 6-8 weeks after 
completing chemotherapy the patient started complaining of eye iritation, extensive lacrimation and 
blurred vison, especially on the left eye. He went for an ophtalmological exam and the diagnosis was tri-
chiasis l. sin et dex susp. The ophtalmologist recommended the patient do eyelash epilation and ordered 
a checkup 4 weeks later to confi rm the diagnosis. After the confi rmation, the patient continued with 
mechanical eyelash epilation every 2-3 months. On the last checkup in 12/2016 the ophtalmologist sug-
gested electroepilation as a permanent solution.
Although docetaxel has been reported to cause itching, puﬃ  ness, or swelling of the eyelids and loss 
of eyelashes is very common among patients recieveng this chemotherapy, this specifi c side eﬀ ect has not 
been seen among our patients. It is important to keep in mind that chometherapeutics can cause signifi cant 
impairment in quality of life long after their last dose has been applied.
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 Iva Badžek1,  Robert Šeparović1
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University Hospital Center, Zagreb, Croatia 
2Department of Radiotherapy and Nuclear Medicine, General Hospital Zadar, Croatia
Infl ammation has an important role in cancer progression, as neutrophils and lymphocytes are 
thought to be signifi cant in tumour immunology and infl ammation. Neutrophil/lymphocyte ratio (NLR) 
is used as a marker of subclinical infl ammation. In several malignancies prognostic value of NLR was 
 demonstrated, indicating that elevated NLR determines worse prognosis of the patients.
The aim of this study was to determine the relationship between pretreatment NLR values and patho-
logic complete response after neoadjuvant therapy in locally advanced breast cancer patients.
Retrospectively we identifi ed 117 patients with breast carcinoma (BC) treated with neoadjuvant che-
motherapy (NCT) at University Hospital for tumors in Zagreb. 79 patients fi nished NCT and underwent 
surgery so theirs data were further analyzed. Pathological complete response (pCR) was defi ned by 
absence of invasive cancer in resected breast and axillary tissue. Value of NLR was measured at the start 
of neoadjuvant treatment by dividing the number of neutrophils by the number of lymphocytes. Median 
age was 55 years. Pathological complete response (pCR) was achieved in 24% BC patients treated with 
NCT (47% luminal B, 53% hormone receptor negative BC). NLR ranged from 0.94 to 5.22. The median NLR 
values were similar in both pCR and non-pCR arm (2.3 vs. 2.38). Pathological complete response (pCR) 
was achieved in 31% patients with low NLR (<2.0) and in 19% of patients with higher NLR (>2.0). There 
were also no signifi cant diﬀ erences regarding BC subtypes. There was no relationship between the pCR 
and pretreatment NLR values.
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in the era of innovative therapies and hystorical review of therapies in Croatia 
Single center experience – University Hospital Centre Zagreb
 Luka Simetić¹,  Krešimir Blažičević²,  Davorin Herceg¹
¹Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb, Croatia, 
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The treatment of locally advanced or metastatic soft tissue sarcomas is still challenging even now in 
the era of novel, innovative therapies. Historically, the sequencing of therapies for soft tissue sarcomas 
(before trabectedin, Yondelis® and pazopanib,Votrient®) was not strictly defi ned. The chemotherapy 
backbone in the fi rst line of treatment in past decades (but also nowadays) were anthracyclines as mono-
therapy or in combination with ifosfamide, dacarbazine etc. Second or third line of treatments were com-
binations of chemotherapy not included in the fi rst line, like gemcitabine or taxanes. With novel therapies 
like trabectedin or pazopanib we observed not just improvements in PFS (progression free survival ) or even 
in OS (overall survival) but defi nitely in quality of life.
We will present our experience with novel therapies and historical review of soft tissue sarcoma treat-
ments in Croatia. We analyzed two cohorts of patients. The fi rst one is historical (around 20pts.), and the 
second one is the cohort of patients treated with trabectedin and pazopanib in second or third line of treat-
ment (around 50 pts). The results of our analysis will be presented as type of medications used in fi rst, 
second or third line of treatment and with time to progression intervals (PFS).
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Cancer cachexia and sarcopenia are frequently observed in cancer patients and associated with poor 
survival. The majority of studies of cancer cachexia and sarcopenia have been done in patients with solid 
tumors of diﬀ erent origin, and there are currently no good predictors of the benefi t of chemotherapy or 
factors that predict survival in advanced cancer.
The purpose of our prospective study was to evaluate prevalence of cachexia and sarcopenia using 
international consensus defi nition and criteria for diagnosis in patients with diagnosed advanced non-
small cell lung cancer (NSCLC) stage IIIB and IV and their relation to chemotherapy toxicity and survival 
prediction. A secondary aim was to compare several biochemical markers (CRP, IL-6, protein and albu-
min) with time to tumor progression in order to assess prognostic value or to guide a treatment.
Between December 2013 and April 2015, the prospective cohort study of one hundred Caucasian 
patients with advanced NSCLC stage IIIB or IV, who were referred consecutively to Department for Respi-
ratory Diseases ‘Jordanovac’ was evaluated. Anthropometric measurements and biochemical data (CRP, 
albumin, protein, IL-6, haemoglobin) together with body composition measurements (total muscle cross 
sectional area, lumbar skeletal muscle index) were obtained for each patient before starting with platinum-
doublet therapy. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured by com-
puterized tomography, and sarcopenia was defi ned using a previously published cut-oﬀ  point. Toxicity 
was assessed after cycle 1 of treatment and time-to-tumor progression was determined prospectively.
One hundred patients with advanced lung cancer were recruited: 67 were male, median age was 64 
years. The median time to disease progression was 187 days. The prevalence of cachexia and sarcopenia in 
study cohort was 69%, and 47%, respectively. CRP, IL-6 and albumin concentration in cachectic, compared 
to non-cachectic patients demonstrated statistically signifi cant diﬀ erence (p=0.020, p=0.040, p=0.003). 
Cachexia and sarcopenia were not found to be predictors of chemotoxicity nor time to tumor progression. 
On the contrary, albumin concentration with established cut-oﬀ  point of 37.5 g/L was clearly proved as the 
predictive factor of both chemotoxicity (OR (95% CI) = 0.85; p<0.001) and survival (HR (95% CI) = 0.55). 
Albumin level has shown to be more important predictive marker of chemotherapy toxicity and survival 
than cachexia and sarcopenia. This approach in clinical sett ings can be used to guide the choice of onco-
logic treatment.
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Purpose of our study was to analyze the characteristics of elderly patients (pts) treated for breast 
cancer (BC).
This is a group of 98 elderly (median 70, range 65-79) pts diagnosed with stage I-III BC from Sep/2001 
until May/2002. Radical surgery was performed in 80/98 women and postoperative radiotherapy in 66/98 
women. The majority of pts had grade 2 (88/98), ductal invasive (49/98), ER and/or PR positive BC (61/98), 
treated with adjuvant CMF chemotherapy (21/98) and TAM (86/98). The most common co-morbidities 
were arterial hypertension (67/98) and atrial fi brillation (17/98). After median FU of 109 mos (range 9-148), 
24/98 pts experienced BC relapse and 5/98 second primary other than BC. Of 51/98 pts who died, 28/51 
died w/o disease relapse. Median disease-free survival was 95 mos (95%CI 74-121); median overall sur-
vival was 118 mos (95% CI ³ 95).
Age should not be the only limiting factor infl uencing antineoplastic therapy in elderly BC pts.
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An increasing trend of use of herbal products within the population of cancer patients has been 
recorded worldwide as well as in our country. A large number of patients without prior consultation with 
their doctors use the plant products in combination with conventional therapy, which can result in a risk 
of the emergence of clinically signifi cant interactions. Interactions that may occur between active princi-
ples deriving from medical plants and the prescribed cytostatic drugs are based on the same pharmacoki-
netic and pharmacodynamic principles as well as the interactions which may occur during administration 
of the actual conventional drugs. Herbal preparations which are used by patients as a supplement to the 
conventional therapy may directly interact with anti-neoplastic drugs and/or drugs to which patients with 
cancer use in the treatment of the associated states of comorbidity. The aim of this study was to analyse the 
potential possibility of arising of interactions with the administration of conventional cytostatic drugs and 
herbal preparations that are most commonly used. Among the most used herbal preparations there are 
those that contain active principles derived from medicinal plants such as: St. John’s wort (Hypericum per-
foratum L.), Echinacea (Echinacea sp.), Ginseng (Panax ginseng C.A. Mey), garlic (Allium sativum L.), green 
tea (Camellia sinensis L. Kuntz e) and peppermint (Mentha x piperita). By systematic review of the literature, 
an overview was made concerning the latest scientifi c knowledge available in electronic databases such as 
MEDLINE (PubMed), EMBASE, AMED, CINHAL, Natural Medicines, Google Scholar and Cochrane 
library database. The review of the current literature has confi rmed the pharmacokinetic and/or pharma-
codynamic mechanisms of interactions that may occur during the simultaneous use of the most widely 
used plants and conventional antineoplastic agents where most of the interaction occurred as the result of 
the mediated metabolic induction or inhibition. St. John’s wort is a very used herbal product that acts as a 
powerful inducer of the CYP3A4 enzyme and P-glycoprotein and its simultaneous administration with 
conventional antineoplastic agents (irinotecan, imatinib), is a result of a reduction in the bioavailability 
and therefore the eﬃ  ciency of the applied drug in therapy. Echinacea is also very often used as an immune-
stimulant and acts as an inhibitor of the CYP3A4 enzyme so that its simultaneous use with conventional 
cytostatic drugs is under an increased risk of occurrence of toxicity. Studies show that Echinacea in com-
bination with etoposide can lead to the occurrence of signifi cant thrombocytopenia. The active principles 
originating from garlic that are applied in combination with an alkylating agent such as cyclophospha-
mide, result in a reduction of genotoxicity, which leads to the conclusion that the garlic performs induc-
tion of CYP2B6 enzyme and reduces the eﬀ ect of cyclophosphamide. The green tea fl avonoids have an 
antagonistic eﬀ ect if applied together with an antineoplastic agent bortezomib, so that their simultaneous 
administration is followed by the absence of a therapeutic eﬀ ect. Tannins that are present in green tea and 
peppermint may create chelate complexes if used with the iron preparations which aﬀ ect their bioavail-
ability. Patients diagnosed with cancer are more inclined to venous thromboembolism. Therefore the 
administration of warfarin with the St. John’s wort and Ginseng is associated with a reduction in eﬃ  cacy 
of the drug due to the direct induction of enzymes that metabolise the S and R stereoisomers of warfarin. 
After examining the available data, we concluded that the use of herbal preparations with the prescribed 
cytostatic drugs chemotherapy is being increased. Therefore information and patients’ education, and the 
advancement of knowledge, att itudes and behaviours of health workers regarding the interactions is nec-
essary in order to prevent potential risks of clinically signifi cant interactions.
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Depression is often under-detected in cancer patients, as well as particularly in breast cancer patients. 
Objective of our study was to check whether breast cancer symptoms are associated with depression. This 
cross sectional study was done from February to April 2015 at Department of Medical Oncology, Univer-
sity Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb. Targeted population was 
the general population of patients diagnosed with breast cancer and treated in tertiary healthcare institu-
tion. We included the consecutive sample of all eligible patients hospitalized or examined in outpatients’ 
clinic during the study period. Patients Health related quality of life (HRQoL) was measured by EORTC 
QLQ - C30 questionnaire, version 3.0. Our key outcome was the result of Beck Depression Inventory II 
(BDI-II). The analysis was performed by robust regression, using NCSS 10 Statistical Software (2015) 
(NCSS, LLC. Kaysville, Utah, USA). Total of 148 breast cancer patients were included. Median (interquar-
tile range) age was 57 (48-65) years. Patients were hospitalized in 30 (20.3%) and treated in outpatients 
clinic in 118 (79.7%) cases. The overall model was signifi cant (P<0.001) with coeﬃ  cient of determination 
after robust weighting, R2=0.58. In other words, 58% of BDI-II variance was predicted by the included vari-
ables. After the adjustment for all other variables in multivariate robust regression analysis, signifi cant 
positive association with depression was found in the cases of tumor stage, number of children, fatigue 
and appetite loss. Signifi cant negative association was found in the cases of age and diarrhea. We can con-
clude that level of breast cancer patients depression is associated with fatique, appetite loss and diarrhea 
independently of diﬀ erent clinical, sociodemographic and vital factors.
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Cardiotoxicity during trastuzumab therapy is most often manifested as a decrease in left ventricular 
ejection fraction (LVEF) ≥ 5% with persistent symptoms or ≥ 10% without symptoms. During adjuvant 
trastuzumab in University Hospital for Tumors, patients are sent every 3 months to a control echocardiog-
raphy to medical cardiotoxicity tracking.
We analyzed the profi le of patients with early HER2 positive breast cancer who developed cardiotox-
icity during adjuvant trastuzumab in our institution. A retrospective review of medical records from the 
Clinic for cardiotoxicity monitoring in University Hospital for Tumors was conducted from 2009 to 2017 
and patients with early HER2 positive breast cancer, who during adjuvant trastuzumab temporarily or 
permanently discontinued treatment due to the development of cardiotoxicity, were selected. From a total 
of 796 patients who underwent adjuvant treatment with trastuzumab 42 (5.28%) developed cardiotoxicity, 
which was reversible in 22 (52.38%), and therapy was only temporarily discontinued, and in 20 (47.62%) 
irreversible forcing trastuzumab treatment withdrawal. The median occurrence of cardiotoxicity was after 
seven cycles of trastuzumab, respectively after 5.5 months of trastuzumab treatment.
Patients were compared with regard to:
1)  Age, with the hypothesis that advanced age is associated with a higher incidence of cardiotoxicity,
2)  Side of adjuvant radiotherapy treatment, with the hypothesis of a higher incidence of cardiotoxic-
ity in patients with left sided breast cancer, and
3)  Body mass index (BMI), with the hypothesis that BMI increases the incidence of cardiotoxicity.
Analysis of medical records revealed that among 42 patients who developed cardiotoxicity during 
trastuzumab treatment, 14 patients (33.33%) were older than 60 years in the time of diagnosis, 21 (50%) 
had a tumor in the left breast with adjuvant radiotherapy treatment performed on the left side of the chest 
and 23 of them (54.76%) had a body mass index greater than 24.99, which according to world literature is 
considered overweight.
The results correspond to data that are listed in the available literature.
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Cannabis sativa L. (Cannabaceae) is one of the fi rst plants cultivated by man and one of the oldest plant 
sources of fi bre, food and remedies. To date, 750 constituents have been identifi ed from cannabis. Out of 
those 750 over 100 are classifi ed as cannabinoids, a unique group of terpenophenolic secondary metabo-
lites. The principal active constituent is delta-9-tetrahydrocannabinol (THC) which binds to endocannabi-
noid receptors to exert its pharmacological activity, including its psychoactive eﬀ ect. The other important 
molecule of current interest is non-psychotropic cannabidiol (CBD). Research of cannabis medical proper-
ties has gained worldwide interest after the discovery of two types of cannabinoid receptors, which are 
G-protein coupled receptors specifi cally responding to endocannabinoids, phytocannabinoids and related 
synthetic cannabimimetic compounds. The medical use of cannabis is still controversial and strongly lim-
ited by unavoidable psychotropic eﬀ ects. However, solid scientifi c data indicated the potential of thera-
peutic value of cannabis in controlling some forms of pain, relieving chemotherapy induced nausea and 
vomiting (CINV) as well as treating cachexia and anorexia with no evidence that giving cannabis to the 
patients would increase illicit drug use in the general population. Various clinical studies have confi rmed 
the antiemetic eﬀ ect of cannabinoids in patients with CINV. It has been reported that cancer patients 
downsized opioid dose after adding cannabis in their pain therapy regimen. Poor chemotherapy response 
and decreased survival is often connected with cachexia. The majority of clinical studies dealing with 
cachexia and anorexia are focused on AIDS patients, but there is some clinical evidence that cannabinoids 
could be benefi cial for patients with cancer-associated anorexia/cachexia. In conclusion, cannabis and can-
nabinoids have an acceptable safety profi le with side eﬀ ects which are generally tolerable and reversible. 
They also show positive results in various clinical trials considering treatment of nausea, vomiting, pain 
and anorexia/cachexia. Further clinical trials are essential for clearly defi ning the role of medical cannabis 
in symptomatic therapy of oncology patients.
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Maintenance therapy is continued use of less potent and toxic drugs when maximum response stabi-
lizes after fi rst-line chemotherapy. It can signifi cantly prolong progression-free survival while maintain an 
acceptable safety profi le and improve QoL. Capecitabine is an oral chemotherapy prodrug that is enzy-
matically converted to 5-fl uorouracil, preferentially in tumor tissue through exploitation of higher intratu-
moral concentrations of thymidine phosphorylase.
The aim of this study was to evaluate safety of generic capecitabine as maintenance therapy after 
fi rst-line chemotherapy in metastatic colorectal cancer.
From 10/2016. - 3/2017. we followed and retrospectively analyzed data from 56 patients who were 
receiving Kapetral as maintenance therapy for metastatic colorectal cancer after 8 cycles of irinotecan-
based induction chemotherapy. Initial capecitabine dose was 1250 mg/m2 taken twice daily during 14 
days in three week cycle. Adverse events were graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (v4.0, 2010). Dose of capecitabine was reduced according to 
spc recommendations.
More then half patients receiving Kapetral had hand and foot syndrome (52%), 36% had diarrhea, 
12,5% hyperbilirubinemia, 14% abdominal cramps, 5% abdominal pain, 9% fatigue, 9% elevated trans-
aminase, 5% hyperlacrimation and 4% of patients had chest tightness. Main dose limiting capecitabine 
monotherapy adverse events were hand and foot syndrome (34%) and diarrhea (12,5%). Adverse events 
were more frequent in females and elderly patients (>65y).
The most common dose-limiting capecitabine monotherapy adverse eﬀ ects are hand-foot syndrome 
and diarrhea and they can signifi cantly diminish quality of life. It is very important to monitor and report 
adverse events in our everyday practice.
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Obesity is a major health issue. It has been associated with increased risk of breast cancer (BC) and 
poorer prognosis. There is evidence that obese patients are less likely to achieve pathological complete 
response (pCR) to neoadjuvant chemotherapy (NCT). Although the underlying mechanism is unknown, 
it is suggested that increased circulating levels of estrogen, insulin, insulin-like growth factor and other 
hormonal factors in obese patients may promote proliferation of breast cancer cells.
The aim of this study was to determine the impact of increased body mass index (BMI) on pathologi-
cal complete response in patients with primary BC treated with neoadjuvant chemotherapy.
Retrospectively we identifi ed 117 patients with breast carcinoma treated with NCT at University 
Hospital for Tumors in Zagreb. 79 patients fi nished neoadjuvant chemotherapy and underwent surgery so 
theirs data were further analyzed. Patients were categorized according to BMI: normal weight (<25 kg/
m2), overweight (25-30 kg/m2) and obese (>30 kg/m2). Pathological complete response (pCR) was defi ned 
by absence of invasive cancer in resected breast and axillary tissue.
Pathological complete response (pCR) was achieved in 24% breast cancer patients treated with NCT 
(47% luminal B, 53% hormone receptor negative BC). 65% of patients had BMI> 25 kg/m2, from which 29% 
had BMI >30 kg/m2. pCR was achieved in 14% of patients with BMI >25 kg/m2, in group with s BMI <25 
kg/m2 pCR was achieved in 43% of patients. Subgroup analysis showed that patients with BMI> 25 kg/m2 
were mostly postmenopausal (90%) and they presented more frequently with luminal B cancer (65%).
Patients with BMI>25 were less likely to achieve a pCR to NCT compared with patients with BMI<25. 
Obese patients present more frequently with larger, locally advanced breast tumors, so they are more fre-
quently candidates for NKT. Further investigation of mechanism of infl uence of BMI on treatment out-
come is needed. Suboptimal dose of chemotherapy for obese patients may also contribute to diminished 
eﬃ  cacy of NCT.
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Strong opioids like morphine are the mainstay of cancer pain treatment. Some patients are reluctant 
to use morphine due to fears and misconceptions. Opiophobia is the reason for undertreatment of chronic 
cancer pain despite the availability and access to these medications.
Objective of our study was to dentify concerns,fears and misconceptions about opioid analgesics 
among cancer patients who previousy hadn’t been treated with these medications.
Spontaneous patients statements concerning fears of opoids were collected when opiod was pre-
scribed for the fi rst time.
Only 12 out of 120 patients had no concerns using opioid analgesics. The majority of our patients 
(108/120) were reluctant to use opioids. In total, 18 diﬀ erent statements that indicate presence of opiopho-
bia, were collected. The fi ve most frequent categories were identifi ed: concerns about tolerance, addiction 
and adverse events, fear that the treatment implies the end of life and fear that the patient might be con-
sidered weak and unable to endure pain.
Most of the patients were unwilling to use prescribed morphine for the treatment of cancer pain. The 
fi ve most frequent categories of statements explaining the reasons for the reluctance to use morphine 
were identifi ed and will be used for patient education and counselling in order to improve cancer pain 
treatment.
